Medtide (FRA:FQ2) Growth Rank: 0 (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FQ2 Medtide Inc FRA:FQ2
31 GF Score
Price €2.18
View Full Analysis

What is Medtide Growth Rank?

Medtide has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

FRA:FQ2
31GF Score
Medtide Inc FRA:FQ2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtide Business Description

Other Exchanges 03880:Hong Kong
Address No. 69, 12 Street, Qiantang District, Zhejiang, Hangzhou, CHN
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score

Get the complete analysis for FRA:FQ2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.18
Price